Pharmacogenomic Considerations in Anesthesia and Pain Management

Christine M. Formea, Wayne T. Nicholson

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations


Today's anesthesiology practitioner often is faced with numerous pharmacologic challenges due to the criticality and comorbidities of patients. Adverse drug reactions in anesthesiology may be further complicated by pharmacodynamic or pharmacokinetic alterations caused by genetics. Anesthesiology was one of the first areas of medicine to demonstrate variability in drug response due to underlying genetic variations in enzymatic activity and contribute to the emergence of pharmacogenetics, the melding of pharmacology and genetics. Early genetic examples in this field include pseudocholinesterase deficiency and malignant hyperthermia. The goal of considering pharmacogenomics in clinical practice is to improve therapeutic outcomes and reduce adverse drug reactions. As new pharmacogenomic information becomes available, the clinician should incorporate emerging pharmacogenomics considerations with established pharmacokinetic and pharmacodynamic information in order to evaluate their total contribution to efficacy and adverse drug reactions.

Original languageEnglish (US)
Title of host publicationPharmacogenomics in Clinical Therapeutics
PublisherJohn Wiley and Sons
Number of pages17
ISBN (Print)9780470657348
StatePublished - Feb 24 2012


  • CYP2D6
  • Codeine
  • Opioid
  • Opioid receptor
  • pain management

ASJC Scopus subject areas

  • General Pharmacology, Toxicology and Pharmaceutics
  • General Medicine


Dive into the research topics of 'Pharmacogenomic Considerations in Anesthesia and Pain Management'. Together they form a unique fingerprint.

Cite this